Ajanta Pharma is established in 1973. Committed to 'Serve Health Care Needs Worldwide', the company produces a comprehensive range of specialty products targeting different therapeutic segments for treatment of patients, customised to each market it is present in. The company's Institutional business comprises of India Business and Africa Business. In India, company is a reliable supplier for various government bodies like Armed forces, government hospitals, canteens, stores department, etc. The product basket for India market includes multivitamins, antibiotics, eye drops, cough syrups, etc. In Africa, the company was the first Generic Company to obtain 'WHO Pre-Qualification' for Anti-Malarial product, a combination of Artemether plus Lumefantrine. It has been innovating on this product since then and has given many new variations for patient convenience and compliance.

As a part of the company’s philosophy to build sustainable and scalable business model, it set its eye on entering the world’s largest and most stringent pharmaceutical market-USA. It carved out select product portfolio which include complex technology products to get the competitive advantage in the market place. It has also made substantial investments in its R&D facilities and thereby acquired required technical and regulatory expertise to penetrate the market. It has an advanced Research & Development Centre for finished formulations and Active Pharmaceutical Ingredient (API) synthesis of different dosage forms.

Business area of the company

Ajanta Pharma is a specialty pharmaceutical company engaged in development, manufacturing and marketing of quality finished dosages. Its business includes Branded Generics in emerging markets of Asia and Africa, Generics in the developed markets of USA and Institution sales. Emerging markets are the major contributors in company’s branded generic business where it is present across Asia and Africa. It has designed customised basket of products for each of these markets and serve wide range of therapeutic segments like Anti-Biotic, Anti-Malarial, Anti-Diabetic, Cardiology, Gynecology, Orthopedics, Pediatric, Respiratory & General Health products.

Ajanta Pharma Ltd.

JB Chemicals & Pharmaceuticals Ltd.

Sanofi India Ltd.

Glenmark Pharmaceuticals Ltd.

Suven Pharmaceuticals Ltd.

Alembic Pharmaceuticals Ltd.

Piramal Enterprises Ltd.

Pfizer Ltd.

Natco Pharma Ltd.

Ipca Laboratories Ltd.

Glaxosmithkline Pharmaceuticals Ltd.

Laurus Labs Ltd.

Eris Lifesciences Ltd.

Granules India Ltd.

Astrazeneca Pharma India Ltd.

HDFC Bank Ltd.

ICICI Bank Ltd.

ITC Ltd.

Reliance Industries Ltd.

Tata Motors Ltd.

Market Cap	16,062 Cr		EPS	50.5		High	1258.95
Stock P/E	24.8		Net Profit Margin	16.7		Low	1249.2

Market Cap	16,062 Cr	ROE	22.8%
P/E Ratio(TTM)	24.8	EPS(TTM)	55.7
P/B Ratio	4.6	Dividend Yield	0.5%
Industry P/E	65.5	Book Value	272.1
		Face Value	2.0

AJANTPHARM